



## Medical Policy Manual **Approved Rev: Do Not Implement until 4/2/26**

### **Naxitamab-gqqk (Danyelza®)**

#### **IMPORTANT REMINDER**

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

#### **POLICY**

#### **INDICATIONS**

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

DANYELZA is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

All other indications are considered experimental/investigational and not medically necessary.

##### Compendial Uses:

- Neuroblastoma

#### **COVERGE CRITERIA**

##### **High-risk neuroblastoma**

Authorization of 12 months may be granted for treatment of high-risk neuroblastoma when all of the following criteria are met:

- The member is 1 year of age or older with relapsed or refractory disease in the bone or bone marrow
- The member has demonstrated a partial or minor response, stable disease, **or progressive disease** with prior therapy
- The requested medication will be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF)

#### **CONTINUATION OF THERAPY**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

#### **APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS**



## Medical Policy Manual Approved Rev: Do Not Implement until 4/2/26

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### **ADDITIONAL INFORMATION**

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### **REFERENCES**

1. Danyelza [package insert]. New York, NY: Y-mAbs Therapeutics, Inc.; March 2024.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed July 23, 2025.

**EFFECTIVE DATE**      4/2/2026

ID\_CHS\_2025